India Enforces Stricter Drug Manufacturing Standards After Fatal Cough Syrup Crisis

By Synovate Team

---

In a landmark move to safeguard public health, the Indian government has announced stricter regulations for pharmaceutical manufacturers following a tragic incident involving contaminated cough syrup. At least 24 children lost their lives after consuming syrup produced by Sresan Pharmaceutical Manufacturer, which was found to contain 48.6% diethylene glycol (DEG) — nearly 500 times the permissible limit.

Authorities have responded decisively, revoking the company’s license and arresting its founder. Investigations are ongoing into pharmacies and medical practitioners connected to the distribution of the syrup. Meanwhile, the government has mandated that all drug manufacturers upgrade their facilities to meet World Health Organization (WHO) standards by December 2024.

While some smaller pharmaceutical companies have expressed concern about meeting the new standards, regulators emphasize that patient safety remains the top priority. Major pharmaceutical firms are expected to step in to prevent potential drug shortages, ensuring essential medicines remain available to the public.

This incident highlights the critical importance of stringent quality control, regulatory oversight, and technological adoption in chemical and pharmaceutical production. Experts believe that these new measures will not only prevent future tragedies but also strengthen India’s position as a global hub for safe and reliable pharmaceutical products.